Nikkei Biotech publishes 2024 “sumo ranking” of Japanese pharma
https://bio.nikkeibp.co.jp/atcl/report/16/082400017/012500075/ According to this analysis, the strongest companies (“Ozeki”) in
https://bio.nikkeibp.co.jp/atcl/report/16/082400017/012500075/ According to this analysis, the strongest companies (“Ozeki”) in
https://bio.nikkeibp.co.jp/atcl/news/p1/24/01/17/11509/ Nihon University and Ebara Corporation study pluripotent cells made
https://bio.nikkeibp.co.jp/atcl/column/16/021500017/012300318/ Silk Strand Pharma, a startup in Tokyo that develops
https://www.nedo.go.jp/news/press/AA5_101715.html A consortium from Kajima, Denka and Takenaka Corporation, under
https://bio.nikkeibp.co.jp/atcl/news/p1/24/01/22/11525/ A research group led by Professor Masato Fujioka and
In a recent article in Nikkei Biotech, the state of
Bildschirmfoto 2024-01-13 um 18.27.01.png
https://www.nedo.go.jp/news/press/AA5_101711.html Hokkaido University, BIPROGY Corporation, and Technoface Co. have developed